Bone Marrow T-Cell Sequestration and Lymphopenia Accompanying Ischemic Stroke are Mediated by T-Cell S1P1 Loss

INTRODUCTION Sequestration of T-cells in bone marrow is a phenomenon recently characterized by our group in the setting of intracranial tumors. Our findings suggest that it is the intracranial location rather than tumor histology that elicits this phenotype. Sequestration is accompanied by lymphopenia and lymphoid organ contraction and is mediated by loss of the S1P1 receptor from the T-cell surface. We now reveal that this phenomenon is not only unique to brain tumors, but accompanies additional intracranial pathologies, most notably ischemic stroke. METHODS Blood, bone marrow, and spleens were collected from mice at day 2, 5, 7, or 14 following stroke via middle cerebral artery occlusion or sham surgery and analyzed by flow cytometry. T-cell S1P1 levels were assessed, along with T-cell counts in each compartment. S1P1 receptor stabilization was achieved with a knock-in model that inhibited receptor internalization. RESULTS Following stroke induction, T-cells accumulated in the bone marrow of injured mice. T-cell numbers peaked at day 7 poststroke before returning to normal levels by day 14. Bone marrow accumulation was accompanied by transient T-cell lymphopenia and splenic contraction following stroke. T-cells in the bone marrow yielded decreased levels of S1P1 on their surface. Conversely, mice with genetically stabilized T-cell S1P1 were protected against sequestration, lymphopenia, and splenic contraction following stroke. CONCLUSION Bone marrow T-cell sequestration occurs transiently following stroke and is mediated by the S1P-S1P1 axis. This may prove to be an adaptive mechanism to limit intracranial inflammation following an initial insult. Better understanding of this phenomenon may uncover a novel mechanism of immune privilege and allow for therapeutic modulation in the setting of stroke, brain tumor, and other types of intracranial injury.

Sphingosine 1-phosphate and inflammation

AbstractSphingosine 1-phosphate (S1P), a sphingolipid mediator, regulates various cellular functions via high-affinity G protein-coupled receptors, S1P1-5. The S1P-S1P receptor signaling system plays important roles in lymphocyte trafficking and maintenance of vascular integrity, thus contributing to the regulation of complex inflammatory processes. S1P is enriched in blood and lymph while maintained low in intracellular or interstitial fluids, creating a steep S1P gradient that is utilized to facilitate efficient egress of lymphocytes from lymphoid organs. Blockage of the S1P-S1P receptor signaling system results in a marked decrease in circulating lymphocytes because of a failure of lymphocyte egress from lymphoid organs. This provides a basis of immunomodulatory drugs targeting S1P1 receptor such as FTY720, an immunosuppressive drug approved in 2010 as the first oral treatment for relapsing–remitting multiple sclerosis. The S1P-S1P receptor signaling system also plays important roles in maintenance of vascular integrity since it suppresses sprouting angiogenesis and regulates vascular permeability. Dysfunction of the S1P-S1P receptor signaling system results in various vascular defects, such as exaggerated angiogenesis in developing retina and augmented inflammation due to increased permeability. Endothelial-specific deletion of S1P1 receptor in mice fed high-fat diet leads to increased formation of atherosclerotic lesions. This review highlights the importance of the S1P-S1P receptor signaling system in inflammatory processes. We also describe our recent findings regarding a specific S1P chaperone, apolipoprotein M, that anchors to high-density lipoprotein and contributes to shaping the endothelial-protective and anti-inflammatory properties of high-density lipoprotein.